SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SCLN 7.72 +0.32 (4.32%)
price chart
Brokerage Firm Price Target on SciClone Pharmaceuticals, Inc.
Brokerage firm BWS Financial downgrades its rating on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). The shares have been rated Hold.
Short Interest of SciClone Pharmaceuticals, Inc. Drops by 10%
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), A drop of 463,119 shares or 10% was seen in the short interest of SciClone Pharmaceuticals, Inc.. Even as the interest dropped from 4,632,538 shares on December 15,2014 to 4,169,419 shares on ...
Buy, Sell, or Hold: SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) develops and commercializes novel medicines for treating a broad range of the world's most serious diseases.
Sector Volume Movers: NN Inc , SciClone Pharmaceuticals Inc , MB Financial Inc
The shares of SciClone Pharmaceuticals Inc (SCLN) accumulated 0.03 points to register gains of 0.4071%. The stock opened the day at 7.36 from whereon it went on to hit the ceiling of 7.51 and the floor value of 7.31.
Stock to Focus SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
[Market Wired] SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) (Trend Analysis) announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Aegis Capital Corp.
SciClone Pharmaceuticals, Inc. Analyst Rating Update
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has received a Neutral rating from research analysts at Zacks with a rank of 3. The company has been rated an average of 3 by 1 Wall Street Analysts.
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3 (SCLN)
What matters is that sales of the company's leading product, Zadaxin increased 28.4% to $32.1 million year-over-year. This shows that demand for the drug has increased at a strong pace.
SciClone Pharmaceuticals Stock Rating Lowered by BWS Financial (SCLN)  Ticker Report
Related articles »  
SciClone Pharmaceuticals Inc.: SciClone Provides 2014 Financial Update and ...
FOSTER CITY, CA -- (Marketwired) -- 01/06/15 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reconfirmed its anticipated year-end 2014 revenue and non-GAAP earnings per share (EPS) guidance, and provided its anticipated revenue guidance ...
SciClone Pharma Backs 2014 Outlook  RTT News
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance  MarketWatch
Related articles »  
SciClone Pharmaceuticals, Inc. (SCLN) Issues FY14 Earnings Guidance
SciClone Pharmaceuticals logo SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) updated its FY14 earnings guidance on Tuesday.
Stocks Underperform for the Week: SciClone Pharmaceuticals Inc , Nuveen ...
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has lost 5.12% during the past week and dropped 15.41% in the past 4 weeks.